Ngā hua rapu - Swapnil Potdar

  • E whakaatu ana i te 1 - 5 hua o te 5
Whakamahine hua
  1. 1
    Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

    Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma mā Erlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, Cecilie Sandberg, Swapnil Potdar, Aija Kyttälä, Iver A. Langmoen, Aki Laakso, Emília Gaál‐Paavola, Markus Perola, Krister Wennerberg, Einar Osland Vik-Mo

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

    Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia mā Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors

    ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors mā Katja Kaipio, Ping Chen, Pia Roering, Kaisa Huhtinen, Piia Mikkonen, Päivi Östling, Laura Lehtinen, Naziha Mansuri, Taina Korpela, Swapnil Potdar, Johanna Hynninen, Annika Auranen, Seija Grénman, Krister Wennerberg, Sampsa Hautaniemi, Olli Carpén

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

    Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets mā Shady Adnan Awad, Daehong Kim, Helena Hohtari, Komal Kumar Javarappa, Tania Brandstoetter, Isabella Maria Mayer, Swapnil Potdar, Caroline A. Heckman, Soili Kytölä, Kimmo Porkka, Eszter Doma, Veronika Sexl, Matti Kankainen, Satu Mustjoki

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia mā Disha Malani, Ashwini Kumar, Oscar Brück, Mika Kontro, Bhagwan Yadav, Monica Hellesøy, Heikki Kuusanmäki, Olli Dufva, Matti Kankainen, Samuli Eldfors, Swapnil Potdar, Jani Saarela, Laura Turunen, Alun Parsons, Imre Västrik, Katja Kivinen, Janna Saarela, Riikka Räty, Minna Lehto, Maija Wolf, Bjørn Tore Gjertsen, Satu Mustjoki, Tero Aittokallio, Krister Wennerberg, Caroline A. Heckman, Olli Kallioniemi, Kimmo Porkka

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: